2028年までのヨーロッパ心血管代謝疾患市場予測 - 新型コロナウイルス感染症の影響と地域別分析（心血管疾患（CVD）、2型糖尿病、高血圧、肥満）、治療法（ACE阻害剤、利尿薬、グルコファージなど）、用量（錠剤） 、注射）、投与経路（経口および静脈内）、エンドユーザー（病院、診療所、在宅医療環境）、流通チャネル（病院の薬局、小売薬局、およびオンライン薬局）
市場紹介
心臓代謝疾患は、以下のような一連の異常と症状を特徴としています。個人が心血管疾患を発症するリスク。高血圧、肥満、インスリン抵抗性、脂質異常症、コレステロールプロファイル（LDL）低下、耐糖能などが症状の一部です。心メタボリックシンドロームに罹患している人は、2 型糖尿病、脳卒中、冠動脈疾患 (CAD)、心血管疾患 (CVD) など、他のいくつかの生命を脅かす病気にかかりやすいです。
さらに、心臓代謝性疾患の有病率の増加により、予測期間中の市場の成長が促進されると予想されます。しかし、低中所得国 (LMIC) における CVD の過小診断により、ヨーロッパの心臓代謝疾患市場の成長が制限されています。
ヨーロッパでは、新型コロナウイルス感染症のパンデミックにより重大な影響が生じています。患者の心臓血管ケアへの影響。既存の心血管疾患を抱えている人は、新型コロナウイルス感染症に感染すると健康状態が悪化して死亡するリスクが高くなります。新型コロナウイルス感染症のパンデミック以来、CVD の予防、診断、治療サービスは大幅に混乱しています。 MedTech Europe によると、新型コロナウイルス感染症による死亡者の約 95% には少なくとも 1 つの基礎疾患があり、最も多い併存疾患は心血管疾患 (65%) でした。また、心臓発作や脳卒中の症状を抱えて病院やその他の医療施設を訪れる人の数が約50％減少し、重篤な健康状態を抱える患者が大幅に滞っている。また、英国のロックダウン後、心臓病変による救急外来の受診者数が前年と比べて31％から88％減少し、市場の成長に悪影響を及ぼした。パンデミックは短期的に市場に大きな影響を与えました。ただし、市場は予測期間中に緩やかなペースで成長すると予想されます。
市場の概要とダイナミクス
ヨーロッパの心臓代謝疾患市場は、2021 年の 267 億 1,750 万米ドルから 2028 年までに 339 億 6,360 万米ドルに達すると予測されています。 2021年から2028年にかけて3.5%のCAGRで成長すると予想されている。Genomics plcが作成した統合リスクツール（IRT）は、今後10年以内に各患者がCVDを発症するリスクを推定するために使用される。同社は、英国の40歳から60歳までの全員にIRTを適用すれば、現在のスクリーニングでは見逃されているCVDのリスクが高い65万人以上を特定できる可能性があると主張している。これとは別に、モノのインターネット (IoT)、クラウド コンピューティング、人工知能 (AI) の最近の進歩により、従来の医療システムは大幅に改善されました。 2021 年 8 月、南ウラル州立大学 (SUSU) の科学者は、AI と IoT を使用して、CVD と糖尿病をより効果的に診断するためのモデルを開発しました。さらに、AIの統合は心臓代謝疾患市場の成長に有利な機会をさらに提供しており、予測期間中引き続きこの市場をサポートすると予想されます。 2021 年 6 月、ACC と GE ヘルスケアは、ACC の Applied Health Innovation Consortium (AHIC) への支援と参加を通じて協力し、心臓病学における AI とデジタル テクノロジーのロードマップを構築し、健康転帰を改善するための新しい戦略を開発しました。
主要な市場セグメント
種類の観点からは、心血管疾患セグメントが占めています。治療に関しては、ACE阻害薬セグメントが2020年のヨーロッパ心代謝性疾患市場で最大のシェアを占めました。用量に関しては、錠剤セグメントが最大のシェアを占めました。 2020 年のヨーロッパの心臓代謝疾患市場。投与経路の観点からは、経口セグメントが 2020 年のヨーロッパの心臓代謝疾患市場で最大のシェアを占めました。エンドユーザーの観点では、病院セグメントがヨーロッパの心臓代謝疾患市場で最大のシェアを占めました。さらに、流通チャネルに基づくと、病院薬局セグメントは2020年に最大の市場シェアを保持しました。
記載されている主要な情報源と企業
ヨーロッパの心臓代謝疾患市場に関するこのレポートを作成するために参照されたいくつかの主要な一次および二次情報源は、以下の企業です。ウェブサイト、年次報告書、財務報告書、国家政府文書、統計データベースなど。このレポートに記載されている主要企業は、Eli Lilly and Company.、Bayer AG、Novartis AG、Boehringer Ingelheim International Gmbh、Novo Nordisk A/S、AstraZeneca、Alnylam Pharmaceuticals, Inc.、興和株式会社です。
購入理由レポート
- ヨーロッパの心臓代謝疾患市場の状況を理解し、高い収益を保証できる市場セグメントを特定する
- 絶えず変化する市場の状況を理解し、競争で優位に立つ
- 売上が最も見込まれるセグメントを特定することにより、ヨーロッパの心臓代謝疾患市場における合併・買収および提携取引を効率的に計画するため
- さまざまなセグメントの市場パフォーマンスの知覚的かつ包括的な分析から知識に基づいたビジネス上の意思決定を行う
- ヨーロッパの心臓代謝疾患市場の市場収益予測を取得する2021 年から 2028 年までのさまざまなセグメントに関する
欧州心血管代謝疾患市場セグメンテーション
タイプ別
- 心血管疾患 ( CVD)
- 2 型糖尿病
- 高血圧
- 肥満
治療別
- ACE阻害剤
- 利尿薬
- グルコファージ
- その他
用量別
- タブレット
- 注射
投与経路別
- 経口
- 静脈内投与
エンドユーザーによる
- 病院
- クリニック
- 在宅ケア設定
販売チャネル別
- 病院薬局
- 小売薬局
- オンライン薬局
国別
- ヨーロッパ
- ドイツ
- イギリス
- フランス
- スペイン
- イタリア
- その他のヨーロッパ
記載されている企業
- イーライ リリー アンド カンパニー。
- バイエル AG
- ノバルティス AG ;
- ベーリンガー インゲルハイム インターナショナル Gmbh
- ノボ ノルディスク A/S
- アストラゼネカ
- Alnylam Pharmaceuticals, Inc.
- 興和株式会社.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Europe Cardiometabolic Diseases market – By Country
2. Europe Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Europe Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Europe Cardiometabolic Diseases Market – Regional Analysis
6.1 Europe Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Europe Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Europe Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Europe Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Europe Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Europe Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Europe Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Europe Cardiometabolic Diseases Market – Geographic Analysis
13.1 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028
13.1.1 Overview
13.1.2 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.3 Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.4 Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.5 Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.6 Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.7 Europe: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.8 Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.9 Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
13.1.9.1 Germany Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.9.1.1 Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.10 Germany: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.11 Germany: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.12 Germany: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.13 Germany: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.14 Germany: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.15 Germany: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UK Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.15.1.1 UK; Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.16 UK: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.17 UK: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.18 UK: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.19 UK: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.20 UK: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.21 UK: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.21.1 France Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.21.1.1 France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.22 France: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.23 France: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.24 France: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.25 France: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.26 France: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.27 France: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Italy Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.27.1.1 Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.28 Italy: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.29 Italy: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.30 Italy: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.31 Italy: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.32 Italy: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.33 Italy: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.33.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.33.1.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.34 Spain: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.35 Spain: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.36 Spain: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.37 Spain: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.38 Spain: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.39 Spain: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.39.1 Rest of Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.39.1.1 Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.40 Rest of Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.41 Rest of Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.42 Rest of Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.43 Rest of Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.44 Rest of Europe: Cardiometabolic Diseases Market, by End User Revenue and Forecast to 2028 (USD Million)
13.1.45 Rest of Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
14.1 Europe: Impact Assessment of COVID-19 Pandemic
15. Europe Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Novartis AG
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Boehringer Ingelheim International GmbH
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Novo Nordisk A/S
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 AstraZeneca
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Alnylam Pharmaceuticals, Inc.
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Kowa Company, Ltd.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 3. Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 5. Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 6. Europe Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 7. Germany Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Germany Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 9. Germany Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Germany Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 11. Germany Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 12. Germany Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 13. UK Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UK Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 15. UK Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UK Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 17. UK Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 18. UK Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 19. France Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. France Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 21. France Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. France Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 23. France Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 24. France Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 25. Italy Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Italy Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 27. Italy Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Italy Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 29. Italy Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 30. Italy Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 31. Spain Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 32. Spain Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 33. Spain Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 34. Spain Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 35. Spain Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 36. Spain Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 38. Rest of Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 39. Rest of Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 40. Rest of Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 41. Rest of Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 42. Rest of Europe Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 43. Organic Developments in the Cardiometabolic Diseases Market
Table 44. Inorganic Developments in the Cardiometabolic Diseases Market
Table 45. Glossary of Terms, Europe Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Europe Cardiometabolic Diseases Market Segmentation
Figure 2. Europe Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Europe Cardiometabolic Diseases Market
Figure 4. Europe Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Europe Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Europe PEST Analysis
Figure 7. Europe Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Europe Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Europe: Cardiometabolic Diseases Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 34. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 35. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
Figure 36. Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 37. UK: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 38. France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 39. Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 40. Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 41. Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 42. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.